# Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

> **NCT00634881** · PHASE1,PHASE2 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 13 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Alemtuzumab i.v.
- **BIOLOGICAL:** Alemtuzumab s.c.

## Key facts

- **NCT ID:** NCT00634881
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2010-01
- **Final completion:** 2012-02-17
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634881, "Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00634881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*